← Organon & Co.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Net Income From Continuing Operations | — | — | — | $917.0m | $1.0b | $864.0m | $187.0m | |
| Net Income (Loss) Attributable to Parent | — | $2.2b | $1.4b | $917.0m | $1.0b | $864.0m | $187.0m | |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | — | $2.3b | $1.4b | $917.0m | $1.0b | — | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | — | ($96.0m) | $0 | $0 | $0 | — | — | |
| Depreciation | $49.0m | $56.0m | $92.0m | $96.0m | $120.0m | $132.0m | $156.0m | |
| Amortization | $284.0m | $86.0m | $103.0m | $116.0m | $116.0m | $145.0m | $205.0m | |
| Amortization of Intangible Assets | — | $86.0m | $103.0m | $116.0m | $116.0m | $145.0m | $205.0m | |
| Amortization Cash Flow | — | — | — | $116.0m | $116.0m | $145.0m | $205.0m | |
| Amortization Of Intangibles | — | — | — | $116.0m | $116.0m | $145.0m | $205.0m | |
| Depreciation Amortization Depletion | — | — | — | $212.0m | $236.0m | $277.0m | $361.0m | |
| Deferred Income Tax Expense (Benefit) | $12.0m | ($32.0m) | ($288.0m) | ($18.0m) | ($485.0m) | ($160.0m) | $63.0m | |
| Deferred Income Tax | — | — | — | ($18.0m) | ($485.0m) | ($160.0m) | $63.0m | |
| Deferred Tax | — | — | — | ($18.0m) | ($485.0m) | ($160.0m) | $63.0m | |
| Share-based Payment Arrangement, Noncash Expense | — | $40.0m | $59.0m | $75.0m | $101.0m | $105.0m | $77.0m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | $11.0m | $17.0m | $22.0m | $15.0m | |
| Share-based Payment Arrangement, Expense | — | $40.0m | $59.0m | $75.0m | $101.0m | $105.0m | $77.0m | |
| Goodwill, Impairment Loss | — | — | — | — | — | — | $301.0m | |
| Impairment of Intangible Assets, Finite-lived | — | — | $7.0m | $9.0m | — | $0 | $9.0m | |
| Impairment of assets | $0 | $0 | $7.0m | $9.0m | $0 | $0 | $9.0m | |
| Impairment of Goodwill | — | — | — | — | $0 | $0 | $301.0m | |
| Asset Impairment Charge | — | — | — | $9.0m | $0 | $0 | $310.0m | |
| Income Tax Expense (Benefit) | — | $496.0m | $178.0m | $205.0m | ($350.0m) | ($57.0m) | $238.0m | |
| Changes in operating assets and liabilities: | ||||||||
| Additional Financial Items | ||||||||
| Increase (Decrease) in Accounts Receivable | — | ($13.0m) | $277.0m | $123.0m | $212.0m | ($383.0m) | ($79.0m) | |
| Increase (Decrease) in Inventories | — | ($34.0m) | $138.0m | $220.0m | $230.0m | $131.0m | $13.0m | |
| Foreign Currency Transaction Gain (Loss), before Tax | — | $5.0m | ($18.0m) | ($11.0m) | ($42.0m) | ($26.0m) | ($14.0m) | |
| Foreign Currency Transaction Gain (Loss), Unrealized | — | — | — | $18.0m | ($40.0m) | $2.0m | $21.0m | |
| Goodwill | — | $4.6b | $4.6b | $4.6b | $4.6b | $4.7b | $4.2b | |
| Acquired in-process research and development and milestones | — | $0 | ($104.0m) | ($107.0m) | ($8.0m) | ($71.0m) | ($30.0m) | |
| Accretion and changes in fair value in contingent consideration | — | — | — | — | $0 | $11.0m | ($50.0m) | |
| Stock-based compensation | $41.0m | $40.0m | $59.0m | $75.0m | $101.0m | $105.0m | $77.0m | |
| Unrealized foreign exchange (gain) loss | $0 | ($5.0m) | $18.0m | ($18.0m) | $40.0m | ($2.0m) | ($21.0m) | |
| Other | $35.0m | ($20.0m) | $55.0m | ($8.0m) | $16.0m | $29.0m | $139.0m | |
| Accounts receivable | $200.0m | $13.0m | ($277.0m) | ($123.0m) | ($212.0m) | $383.0m | $79.0m | |
| Inventories | ($91.0m) | $34.0m | ($138.0m) | ($220.0m) | ($230.0m) | ($131.0m) | ($13.0m) | |
| Other current assets | ($105.0m) | $80.0m | $353.0m | ($43.0m) | ($10.0m) | ($236.0m) | ($32.0m) | |
| Trade accounts payable | ($35.0m) | $37.0m | $663.0m | ($237.0m) | $163.0m | ($157.0m) | ($217.0m) | |
| Accrued and other current liabilities | ($86.0m) | $12.0m | $329.0m | $172.0m | $102.0m | ($101.0m) | ($142.0m) | |
| Income taxes payable | ($590.0m) | ($118.0m) | ($119.0m) | $7.0m | $16.0m | ($65.0m) | ($61.0m) | |
| Dermavant acquisition, net of cash acquired | — | — | — | $0 | $0 | ($166.0m) | ($75.0m) | |
| Purchase of product rights and asset acquisition | $0 | $0 | ($192.0m) | ($124.0m) | ($2.0m) | ($105.0m) | ($124.0m) | |
| Employee withholding taxes related to stock-based awards | — | $0 | $0 | ($11.0m) | ($17.0m) | ($22.0m) | ($15.0m) | |
| Beginning Cash Position | — | — | — | $737.0m | $706.0m | $693.0m | $675.0m | |
| Cash Flow From Continuing Financing Activities | — | — | — | ($433.0m) | ($569.0m) | ($368.0m) | ($561.0m) | |
| Cash Flow From Continuing Investing Activities | — | — | — | ($420.0m) | ($260.0m) | ($513.0m) | ($390.0m) | |
| Cash From Discontinued Financing Activities | — | — | ($356.0m) | $0 | — | — | — | |
| Cash From Discontinued Investing Activities | — | — | ($356.0m) | $0 | $0 | — | — | |
| Change In Account Payable | — | — | — | ($237.0m) | $163.0m | ($157.0m) | ($217.0m) | |
| Change In Accrued Expense | — | — | — | $172.0m | $102.0m | ($101.0m) | ($142.0m) | |
| Change In Income Tax Payable | — | — | — | $7.0m | $16.0m | ($65.0m) | ($61.0m) | |
| Change In Inventory | — | — | — | ($220.0m) | ($230.0m) | ($131.0m) | ($13.0m) | |
| Change In Other Current Assets | — | — | — | ($43.0m) | ($10.0m) | ($236.0m) | ($32.0m) | |
| Change In Other Working Capital | — | — | — | ($8.0m) | $16.0m | $29.0m | $139.0m | |
| Change In Payable | — | — | — | ($230.0m) | $179.0m | ($222.0m) | ($278.0m) | |
| Change In Payables And Accrued Expense | — | — | — | ($58.0m) | $281.0m | ($323.0m) | ($420.0m) | |
| Change In Receivables | — | — | — | ($123.0m) | ($212.0m) | $383.0m | $79.0m | |
| Change In Tax Payable | — | — | — | $7.0m | $16.0m | ($65.0m) | ($61.0m) | |
| Change In Working Capital | — | — | — | ($452.0m) | ($155.0m) | ($278.0m) | ($247.0m) | |
| Changes In Account Receivables | — | — | — | ($123.0m) | ($212.0m) | $383.0m | $79.0m | |
| Changes In Cash | — | — | — | $5.0m | ($30.0m) | $58.0m | ($251.0m) | |
| End Cash Position | — | — | — | $706.0m | $693.0m | $675.0m | $574.0m | |
| Financing Cash Flow | — | — | — | ($433.0m) | ($569.0m) | ($368.0m) | ($561.0m) | |
| Free Cash Flow | — | — | — | $431.0m | $538.0m | $588.0m | $384.0m | |
| Investing Cash Flow | — | — | — | ($420.0m) | ($260.0m) | ($513.0m) | ($390.0m) | |
| Net Business Purchase And Sale | — | — | — | $0 | $0 | ($166.0m) | ($75.0m) | |
| Net Foreign Currency Exchange Gain Loss | — | — | — | ($18.0m) | $40.0m | ($2.0m) | ($21.0m) | |
| Net Intangibles Purchase And Sale | — | — | — | ($231.0m) | ($10.0m) | ($176.0m) | ($154.0m) | |
| Net PPE Purchase And Sale | — | — | — | $7.0m | $1.0m | $4.0m | $1.0m | |
| Operating Gains Losses | — | — | — | ($18.0m) | $40.0m | ($2.0m) | ($94.0m) | |
| Other Cash Adjustment Outside Changein Cash | — | — | $0 | $0 | $0 | — | — | |
| Other Non Cash Items | — | — | — | $133.0m | $39.0m | $133.0m | $43.0m | |
| Purchase Of Business | — | — | — | $0 | $0 | ($166.0m) | ($75.0m) | |
| Purchase Of Intangibles | — | — | — | ($231.0m) | ($10.0m) | ($176.0m) | ($154.0m) | |
| Sale Of PPE | — | — | — | $7.0m | $1.0m | $4.0m | $1.0m | |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement | — | — | — | — | — | ($1.0m) | $0 | |
| Derivative, Gain (Loss) on Derivative, Net | — | — | — | $0 | $0 | — | — | |
| Net Cash Provided by (Used in) Operating Activities | ($253.0m) | ($97.0m) | $298.0m | $0 | $0 | $939.0m | $700.0m | |
| Cash flows from investing activities: | ||||||||
| Payments to Acquire Property, Plant, and Equipment | ($92.0m) | $255.0m | $192.0m | $196.0m | $251.0m | $175.0m | $162.0m | |
| Proceeds from sale of property, plant and equipment | $4.0m | $5.0m | $7.0m | $7.0m | $1.0m | $4.0m | $1.0m | |
| Capital Expenditure Reported | — | — | — | ($196.0m) | ($251.0m) | ($175.0m) | ($162.0m) | |
| Net Cash Flows Used in Investing Activities | — | — | — | ($420.0m) | ($260.0m) | ($513.0m) | ($390.0m) | |
| Net Cash Provided by (Used in) Investing Activities | ($14.0m) | ($8.0m) | $0 | $0 | — | ($513.0m) | ($390.0m) | |
| Cash flows from financing activities: | ||||||||
| Proceeds from Issuance of Long-term Debt | — | $0 | $9.5b | $0 | $80.0m | $1.2b | $1.1b | |
| Proceeds from debt | $0 | $0 | $9.5b | $0 | $80.0m | $1.2b | $1.1b | |
| Payment of long-term debt issuance costs | $0 | $0 | ($118.0m) | $0 | $0 | ($38.0m) | $0 | |
| Issuance Of Debt | — | — | — | $0 | $80.0m | $1.2b | $1.1b | |
| Long Term Debt Issuance | — | — | — | $0 | $80.0m | $1.2b | $1.1b | |
| Net Issuance Payments Of Debt | — | — | — | ($108.0m) | ($258.0m) | ($11.0m) | ($458.0m) | |
| Net Long Term Debt Issuance | — | — | — | ($108.0m) | ($258.0m) | ($11.0m) | ($458.0m) | |
| Net Short Term Debt Issuance | — | — | ($1.5b) | $0 | $0 | — | — | |
| Short Term Debt Issuance | — | — | $0 | $0 | — | — | — | |
| Repayments of Long-term Debt | — | $0 | $112.0m | $108.0m | $338.0m | $1.2b | $1.5b | |
| Gain on debt repurchase | — | — | — | — | $0 | $0 | ($73.0m) | |
| Repayments of debt | $0 | $0 | ($112.0m) | ($108.0m) | ($338.0m) | ($1.2b) | ($1.5b) | |
| Long Term Debt Payments | — | — | — | ($108.0m) | ($338.0m) | ($1.2b) | ($1.5b) | |
| Repayment Of Debt | — | — | — | ($108.0m) | ($338.0m) | ($1.2b) | ($1.5b) | |
| Short Term Debt Payments | — | — | ($1.5b) | $0 | $0 | — | — | |
| Dividends paid | — | $0 | $145.0m | $290.0m | $294.0m | $297.0m | $88.0m | |
| Dividend payments | $0 | $0 | ($145.0m) | ($290.0m) | ($294.0m) | ($297.0m) | ($88.0m) | |
| Cash Dividends Paid | — | — | — | ($290.0m) | ($294.0m) | ($297.0m) | ($88.0m) | |
| Common Stock Dividend Paid | — | — | — | ($290.0m) | ($294.0m) | ($297.0m) | ($88.0m) | |
| Net Other Financing Charges | — | — | — | ($35.0m) | ($17.0m) | ($60.0m) | ($15.0m) | |
| Net Cash Flows Used in Financing Activities | — | — | — | ($433.0m) | ($569.0m) | ($368.0m) | ($561.0m) | |
| Net Cash Provided by (Used in) Financing Activities | — | ($153.0m) | ($356.0m) | $0 | $0 | ($368.0m) | ($561.0m) | |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | $0 | $23.0m | ($36.0m) | $17.0m | ($76.0m) | $150.0m | |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | $0 | $0 | $23.0m | ($36.0m) | $17.0m | ($76.0m) | $150.0m | |
| Effect Of Exchange Rate Changes | — | — | — | ($36.0m) | $17.0m | ($76.0m) | $150.0m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | ($249.0m) | $667.0m | ($31.0m) | ($13.0m) | ($18.0m) | ($101.0m) | |
| Net Decrease in Cash and Cash Equivalents | $75.0m | ($249.0m) | $667.0m | ($31.0m) | ($13.0m) | ($18.0m) | ($101.0m) | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | $12.0m | $737.0m | $706.0m | $693.0m | $675.0m | $574.0m | |
| Cash and Cash Equivalents, Beginning of Period | $0 | $12.0m | $737.0m | $706.0m | $693.0m | $675.0m | $574.0m | |
| Supplemental disclosure of cash flow information: | ||||||||
| Change In Cash Supplemental As Reported | — | — | — | ($31.0m) | ($13.0m) | ($18.0m) | ($101.0m) | |
| Income Taxes Paid, Net | — | — | — | — | — | — | $287.0m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.